A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in T2DM Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2012
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Dec 2010 Actual initiation date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2008 New trial record.